1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,840 | 0,878 | 17:13 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.05. | Nanoform Finland Oyj: Nanoform Q1 2026 report - Record first quarter revenue, income and gross margin, first exclusivity deal signed around our Biologics technology | 462 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | May 19, 2026 at 08:10:00 EEST
Record first quarter revenue, income and gross margin. Revenue grew by 45%, gross margin reached 94% and operating costs fell by... ► Artikel lesen | |
| 12.05. | Nanoform Finland Oyj: Inside information: Nanoform Signs First Exclusivity Agreement for Ultra-High Concentration Subcutaneous Delivery | 644 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | May 12, 2026 at 08:00:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it has... ► Artikel lesen | |
| NANOFORM FINLAND Aktie jetzt für 0€ handeln | |||||
| 21.04. | Nanoform Finland Oyj: Resolutions of Nanoform Finland Plc's Annual General Meeting on April 21, 2026 | 476 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | April 21, 2026 at 12:20:00 EEST
Nanoform Finland Plc (the "Company" or "Nanoform") held its Annual General Meeting for 2026 on April 21, 2026 at the Company's... ► Artikel lesen | |
| 02.03. | Nanoform Finland Oyj: The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees | 796 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | March 02, 2026 at 08:10:00 EET
Helsinki, Finland - The Annual General Meeting of Nanoform Finland Plc ("Nanoform") has on 15 April 2025 authorized the company's... ► Artikel lesen | |
| 26.02. | Nanoform Finland Oyj: Nanoform Q4 & FY2025 report - Next: the submission of a marketing authorization application for Nanoenzalutamide in Europe | 2.309 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | February 26, 2026 at 08:10:00 EET
Product kernel strategy continues to gain traction. Nanoenzalutamide: pivotal human fed and fasted study concluded, three more... ► Artikel lesen | |
| 07.01. | Nanoform Finland Oyj: Inside information: Nanoform starts change negotiations as part of announced new midterm business targets for 2030 | 1.023 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | January 07, 2026 at 08:05:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform") starts change negotiations in accordance with the Act on Cooperation.... ► Artikel lesen | |
| 16.12.25 | Nanoform Finland Oyj: Inside information: Nanoform announces new midterm business targets for 2030 | 1.495 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | December 16, 2025 at 07:00:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced new midterm... ► Artikel lesen | |
| 12.11.25 | Nanoform Finland Oyj: Nanoform Q3 report: Momentum in kernels continues, commercial cGMP manufacturing license received, first near-term target for 2026 set | 1.801 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | November 12, 2025 at 08:10:00 EET
Our product kernels see good momentum. Nanoenzalutamide progresses with the fed arm of the pivotal human study. Licensing and... ► Artikel lesen | |
| 11.11.25 | Nanoform Finland Oyj: Inside information made public: Nanoform Granted European Commercial cGMP Manufacturing License | 799 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | November 11, 2025 at 08:00:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that... ► Artikel lesen | |
| 27.10.25 | Nanoform Finland Oyj: Nanoform Partners With Revio Therapeutics To Develop Long-Acting Locally-Delivered Hydrogel Nanoformulation To Treat Glioma | 928 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | October 27, 2025 at 09:10:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced a partnership... ► Artikel lesen | |
| 14.10.25 | Nanoform Finland Oyj: Nanoform Outlicenses Nanoencorafenib And Signs Development And Commercialisation Agreement With A.forall And IMGA | 962 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | October 14, 2025 at 09:30:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it has... ► Artikel lesen | |
| 30.09.25 | Nanoform Finland Oyj: Nanoform Expands Commercial Presence In Asia With A&ls Pharma In South Korea | 958 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | September 30, 2025 at 09:30:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced it has entered... ► Artikel lesen | |
| 21.08.25 | Nanoform Finland Oyj: Nanoform Q2 2025 report: Continued progress on many fronts, supportive first preliminary pivotal nanoenzalutamide study results | 1.802 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | August 21, 2025 at 08:10:00 EEST
First preliminary pivotal study results supportive for project Nanoenzalutamide to continue to progress towards the markets.... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 20,900 | +4,24 % | Formycon: Vorstand im Roundtable bei mwb research - Video | Der Vorstand der Formycon AG war beim -Online-Roundtable von mwb research zu Gast und hat dort unter anderem über Zahlen, Perspektiven und die Entwicklungen bei den diversen Biosimilar-Projekten des... ► Artikel lesen | |
| ONTO INNOVATION | 277,00 | +5,64 % | Three Analysts Reaffirm Their Buy Ratings On Onto Innovation (ONTO) Stock | ||
| SMOLTEK NANOTECH | 0,186 | -5,82 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.06.2026 | Das Instrument G85 CA35958L1013 FUERTE METALS CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 09.06.2026 und ex Kapitalmassnahme am 10.06.2026 The instrument G85 CA35958L1013 FUERTE METALS CORP.... ► Artikel lesen | |
| RIBER | 12,940 | -1,82 % | Riber: Margen steigen, KI-Boom treibt - Hidden Champion vor nächsten Kursschub? | Hightech "Made in France" mit Rückenwind durch KI und Photoniks: Riber verbessert trotz leicht rückläufigem Umsatz deutlich seine Profitabilität und könnte vor einem neuen Wachstumszyklus stehen. Riber... ► Artikel lesen | |
| GOMSPACE | 1,710 | +5,36 % | GomSpace Group AB: Annual general meeting held in GomSpace Group AB (publ) | Today, the annual general meeting of 2026 has been held in GomSpace Group AB (publ) (the "Company" or "GomSpace"). Below follows a summary of the decisions taken by the annual general meeting (all... ► Artikel lesen | |
| SOLESENCE | 1,290 | +15,18 % | Solésence, Inc.: Solésence Reports Fourth Quarter and Full-Year 2025 Financial Results | Full Year 2025 record revenue of $62.1 million ROMEOVILLE, Ill., March 31, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty... ► Artikel lesen | |
| KOPIN | 4,509 | +1,65 % | Fabric.AI (Nasdaq: FABC) and Kopin Corporation (Nasdaq: KOPN) Appoint Bill Maffucci to Lead Development of Neural I/o MicroLED Optical Interconnect Chip Program | NEW YORK, NY, May 06, 2026 (GLOBE NEWSWIRE) -- Fabric.AI (Nasdaq: FABC) ("Fabric.AI" or "the Company"), an AI infrastructure company developing a suite of fabless semiconductor technologies for next-generation... ► Artikel lesen | |
| OBDUCAT | 0,056 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.12.2025 | Das Instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 31.12.2025 und ex Kapitalmassnahme am 02.01.2026 The instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY... ► Artikel lesen | |
| NVE | 102,00 | +4,08 % | Dividendenbekanntmachungen (18.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A2A SPA IT0001233417 - 0,104 EUR AIR LIQUIDE SA FR0000120073 - 3,7 EUR ALCOA CORPORATION CDIS AU0000339426 0,1 USD 0,086 EUR ALLISON... ► Artikel lesen | |
| VEECO INSTRUMENTS | 63,22 | +2,23 % | Veeco's new LUMINA+ MOCVD system qualified by Ennostar | ||
| NANOVIRICIDES | 1,220 | +2,52 % | As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies | SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides... ► Artikel lesen | |
| GAUZY | 0,620 | +3,37 % | Gauzy Ltd. Announces Receipt of Nasdaq Notice Regarding Delayed Filing of Annual Report on Form 20-F | TEL AVIV, Israel, May 26, 2026 (GLOBE NEWSWIRE) -- Gauzy Ltd. (NASDAQ: GAUZ) ("Gauzy" or the "Company"), a global leader in vision and light control technologies, today announced that on May 19, 2026... ► Artikel lesen | |
| DOTZ NANO | 0,023 | +6,54 % | DOTZ NANO LIMITED: Notice of Extraordinary General Meeting/Proxy Form | ||
| ACACIA RESEARCH | 3,940 | -0,51 % | Acacia Research Q1 2026 slides show mixed results, strong liquidity | ||
| ADVANCE ZINCTEK | 0,412 | 0,00 % | ADVANCE ZINCTEK LIMITED: Change of Director's Interest Notice - Lev Mizikovsky |
NANOFORM FINLAND OYJ gehört der Branche Nanotechnologie an. Mit einer aktuellen Kursveränderung von -0,028 (-3,46 %) liegt der Kurs bei 0,781 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOFORM FINLAND OYJ finden Sie auf Wallstreet Online.